Literature DB >> 22337711

Examining the effectiveness of antipsychotic medication in first-episode psychosis.

Mark Taylor1, Jonathan Cavanagh, Richard Hodgson, Jari Tiihonen.   

Abstract

The regular use of antipsychotic medication is known to improve overall outcomes and diminish risk of relapse, but applying the results of randomised controlled trials (RCTs) into routine clinical practice is not always straightforward. Furthermore, psychiatrists, service users and policy makers can have trouble keeping up with the burgeoning and, at times, conflicting results from research trials, meta-analysis and systematic reviews. In this paper we examine the differences between efficacy and effectiveness trials with regard to antipsychotic medication with a focus on first-episode psychosis, after reviewing the relative contribution of antipsychotic medication to outcomes in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22337711     DOI: 10.1177/0269881112439252

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  7 in total

1.  The RAISE Connection Program for Early Psychosis: Secondary Outcomes and Mediators and Moderators of Improvement.

Authors:  Leslie Marino; Ilana Nossel; Jean C Choi; Keith Nuechterlein; Yuanjia Wang; Susan Essock; Melanie Bennett; Karen McNamara; Sapna Mendon; Lisa Dixon
Journal:  J Nerv Ment Dis       Date:  2015-05       Impact factor: 2.254

2.  Implementing Coordinated Specialty Care for Early Psychosis: The RAISE Connection Program.

Authors:  Lisa B Dixon; Howard H Goldman; Melanie E Bennett; Yuanjia Wang; Karen A McNamara; Sapna J Mendon; Amy B Goldstein; Chien-Wen J Choi; Rufina J Lee; Jeffrey A Lieberman; Susan M Essock
Journal:  Psychiatr Serv       Date:  2015-03-16       Impact factor: 3.084

3.  Time to discontinuation of antipsychotic drugs in a schizophrenia cohort: influence of current treatment strategies.

Authors:  Rune A Kroken; Eirik Kjelby; Tore Wentzel-Larsen; Liv S Mellesdal; Hugo A Jørgensen; Erik Johnsen
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

4.  Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes.

Authors:  J M Stevenson; J L Reilly; M S H Harris; S R Patel; P J Weiden; K M Prasad; J A Badner; V L Nimgaonkar; M S Keshavan; J A Sweeney; J R Bishop
Journal:  Transl Psychiatry       Date:  2016-02-23       Impact factor: 6.222

Review 5.  Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.

Authors:  Georgia L Stevens; Gail Dawson; Jacqueline Zummo
Journal:  Early Interv Psychiatry       Date:  2015-09-25       Impact factor: 2.732

6.  Effects of Recovery-Orientation on the Use of Forced Medication and Maximum Daily Drug Dose: The "Weddinger Modell".

Authors:  Klara Czernin; Felix Bermpohl; Alexandre Wullschleger; Lieselotte Mahler
Journal:  Front Psychiatry       Date:  2021-12-15       Impact factor: 4.157

7.  Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness.

Authors:  Petros Drosos; Erik Johnsen; Christoffer Andreas Bartz-Johannessen; Tor Ketil Larsen; Solveig Klæbo Reitan; Maria Rettenbacher; Rune Andreas Kroken
Journal:  World J Psychiatry       Date:  2022-03-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.